The history of multiple sclerosis: the changing frame of the disease over the centuries

Journal of the Neurological Sciences

Volumn 277, Issue SUPPL. 1, 2009, Pages

  Murray, T Jock ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Aetiology; Diagnosis; Histopathology; History; Multiple sclerosis; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ARSENIC; ATROPINE; BELLADONNA ALKALOID; CURARE; ERGOT ALKALOID; HERBACEOUS AGENT; HISTAMINE; HYOSCYAMINE; IMMUNOMODULATING AGENT; POTASSIUM IODIDE; QUININE; SILVER NITRATE; SOLANINE; STRYCHNINE; VACCINE; VERATRUM ALBUM EXTRACT;

ANTINEOPLASTIC ACTIVITY; DIET THERAPY; EDITORIAL; ELECTROSTIMULATION THERAPY; ENVIRONMENTAL FACTOR; GEOGRAPHY; HEREDITY; HISTORY OF MEDICINE; HYDROTHERAPY; IMMUNOLOGY; INFECTION; KINESIOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VERATRUM;

EID: 59349103787     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(09)70003-6     Document Type: Editorial

References (21)

1. Rosenberg C. Framing disease: illness, society, and history. In: Rosenberg C., and Golden J. (Eds). Framing Disease: Studies in Cultural History (1992), Rutgers University Press, New Brunswick xiii-xxvi
2. Murray T. Multiple sclerosis: the history of a disease (2005), Demos, New York
3. Ebers G.C., Sadovnick A.D., Risch N.J., and Canadian Collaborative Study Group. A genetic basis for familial aggregation in multiple sclerosis. Nature 377 (1995) 150-151
4. Young I.R., Hall A.S., Pallis C.A., Legg N.J., Bydder G.M., and Steiner R.E. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 2 (1981) 1063-1066
5. Lublin F.D., Reingold S.C., and National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
6. Gay D., and Dick G. Is multiple sclerosis caused by an oral spirochaete?. Lancet 2 (1986) 75-77
7. Marshall V. Multiple sclerosis is a chronic central nervous system infection by a spirochetal agent. Med Hypoth 25 (1988) 89-92
8. Ascherio A. Epstein Barr virus in the development of multiple sclerosis. Expert Rev Neurother 8 (2008) 331-333
9. Lunemann J.D., Kamradt T., Martin R., and Munz C. Epstein Barr virus: environmental trigger of multiple sclerosis?. J Virol 81 (2007) 6777-6784
10. Brain W. Critical review: disseminating sclerosis. Q J Med 23 (1930) 343-391
11. Metz L.M., Zhang Y., Yeung M., Patry D.G., Bell R.B., Stoian C.A., et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55 (2004) 756
12. Miller H., Newell D.J., and Ridley A. Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin. Lancet 1 (1961) 127-129
13. Rose A.S., Kuzma J.W., Kurtzke J.F., Namerow N.S., Sibley W.A., and Tourtellotte W.W. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo final report. Neurology 20 (1970) 1-59
14. Coles A., and CAMMS 223 Study Group. Alemtuzumab compared with subcutaneous high-dose IFNβ-1a in treatment-naive relapsing remitting multiple sclerosis: primary efficacy outcomes of CAMMS223 at 3 years. Neurology 70 Suppl 1 (2008) A22.006
15. Romine J.S., Sipe J.C., Koziol J.A., Zyroff J., and Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing remitting multiple sclerosis. Proc Assoc Am Physicians 111 (1999) 35-44
16. Rice G.P., Filippi M., Comi G., and Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 54 (2000) 1145-1155
17. Brown J.R., Beebe G.W., Kurtzke J.F., Loewenson R.B., Silberberg D.H., and Tourtellotte W.W. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 29 (1979) 3-23
18. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
19. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al., The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45 (1995) 1268-1276
20. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al., The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39 (1996) 285-294
21. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504